As Pai et al. explained in a low tumor burden state, combination of anti-CTLA-4 and anti-PD-1 therapy antibodies activates T-cells to secrete high-levels of intratumoral IFN-γ, which in turn killed T cells and led to tumor immune escape [130] (Fig. 5). Here, CTLA4 is linked to neoplasm.